via Shirley Ryan AbilityLab
A team of scientists — led by Yamin Zhang, PhD, and Colin Franz, MD, PhD, at Shirley Ryan AbilityLab and John Rogers, PhD, at Northwestern University — has developed novel technology with the potential to change the future of drug delivery.
The device developed represents the first implantable drug delivery system that is triggered by external light sources of different wavelengths, and not by electronics. It also is the first to be absorbable by the body (avoiding surgical extraction) while still allowing active control and programming by the operator (e.g., a doctor, nurse or patient). A study highlighting the device has been published today in the Proceedings of the National Academy of Sciences (PNAS).
“This technology represents a breakthrough addressing shortfalls of current drug delivery systems — one that could have important and sweeping implications for everything from the opioid epidemic to how cancer treatments are precisely delivered,” said Colin Franz, MD, PhD, physician-scientist at Shirley Ryan AbilityLab.
Current implantable drug delivery systems are used to treat medical conditions ranging from chronic pain and muscle spasticity to cancer and diabetes. Passive systems enable gradual release of drugs and don’t require extraction at the end of their use, but they cannot be actively controlled by the user (e.g., turning drug delivery off, up or down). Conversely, active systems that allow programmable drug release require power supplies and electronic parts, and eventually require a second surgery for device extraction.
To test this novel technology, researchers surgically implanted it into the right sciatic nerve of individual rats. Each device contained three drug reservoirs filled with lidocaine, a common nerve-pain-blocking drug. Then, three LEDs were placed over the implantation sites to trigger release of the drug. Subsequent testing showed marked pain relief among the rats. Moreover, researchers were able to achieve different patterns of pain relief depending on the LED color-light sequencing.
“We found this approach to be an effective, safe and non-addictive alternative to systemically delivered pain medications,” said Northwestern University’s John Rogers, PhD. “Additionally, it can be scaled. Although we used a combination of three LEDs in our proof-of-concept testing, moving forward we can potentially increase it up to 30 different LED wavelengths, offering many more programs for pain relief.”
In future studies, the scientific team will review various safety elements prior to seeking U.S. Food and Drug Administration (FDA) clearance for human clinical trials.
“This technology has many promising implications in rehabilitation medicine and beyond, and the collaboration among physicians, material scientists and biomedical engineers at Shirley Ryan AbilityLab and Northwestern University is rapidly accelerating clinically relevant discoveries,” said Dr. Franz, who also is an assistant professor of Physical Medicine and Rehabilitation and Neurology at Northwestern University Feinberg School of Medicine.
Original Article: Shirley Ryan AbilityLab and Northwestern University Invent Self-Powered Drug Delivery System
More from: Shirley Ryan AbilityLab | Northwestern University
The Latest Updates from Bing News
Go deeper with Bing News on:
Implantable drug delivery system
- Implantable Drug Eluting Devices Market is set to experience a significant growth of 6.0% CAGR from 2022 to 2029
Report of 326 Pages] From 2022 to 2029, the global implantable drug eluting device market is anticipated to grow significantly at a 6.0% CAGR, with a market value of about US$ 12.8 Bn in 2022.
- UnitedHealthcare to cover Senseonics Eversense E3 CGM
Senseonics (NYSE:SENS) announced that UnitedHealthcare intends to begin providing coverage for its Eversense E3 CGM.
- Silicones for Drug-Delivery Applications
(click image to enlarge) Drug-delivery systems are some of the most rapidly proliferating products in healthcare today, with the implantable-systems market growing at a double-digit clip. As ...
- Researchers use AI models to advance drug delivery system for chronic eye diseases
Wilmer Eye Institute, Johns Hopkins Medicine researchers say they have used artificial intelligence models and machine-learning algorithms to successfully predict which components of amino acids that ...
- AI used to advance drug delivery system for glaucoma and other chronic diseases
In 2020, the Food and Drug Administration approved an implantable device ... studies investigating drug delivery using peptides have shown how effective this system can be, but they wanted to ...
Go deeper with Bing News on:
Drug delivery system
- Taking the Needle out of Vaccine Delivery
Oslo, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) and Oxford, UK-based aVaxziPen, have joined forces to develop two new vaccines using aVaxziPen's needle-free vaccine delivery ...
- Subcutaneous Drug Delivery Device Market: Trends, Opportunities and Competitive Analysis [2023-2028]
Trends, opportunity and forecast in the global subcutaneous drug delivery device market from 2017 to 2028 by product (prefilled syringes, pen injectors, auto-injectors, wearable injectors, and ...
- New folate-targeting magnetic microrobot system shows great potential in cancer treatment
The limited ability of microrobots to assist drugs in entering cells hinders their therapeutic efficacy. To address this, the cancer-targeting molecule folic acid (FA) was introduced to microrobots to ...
- Team develops magnetic microrobots with folate to promote targeted drug delivery to cancer cells
The limited ability of microrobots to assist drugs in entering cells hinders their therapeutic efficacy. To address this, a research team, reporting in Cyborg and Bionic Systems, has introduced the ...
- Why novel drug delivery systems are taking centre stage in the pharmaceutical industry?
NDDSs have gained much attention, especially in cancer therapy and immunodeficiency diseases due to their high efficacy and stability.